Together, Bayer AG and Peking University (PKU) will accelerate scientific research on cutting-edge technologies throughout the pharmaceutical value chain and support the translation of fundamental pharmaceutical research into drug discovery and development.
The U.S. subsidiary of Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals, and Sanofi have announced a partnership to co-develop and co-commercialize asset TEV’574, which is presently undergoing Phase 2b clinical trials for the treatment of Crohn’s disease and ulcerative colitis, two forms of inflammatory bowel disease.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5378
Published Date: Nov 16, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are rising geriatric population, surge in prevalence of constipation, and growth in healthcare infrastructure.
The market size of osmotic laxative is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2024-2036.
The major players in the market are GlaxoSmithKline, Bayer AG, Pfizer Inc., Sanofi, and others.
The chronic constipation segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.